Literature DB >> 3873337

The large sialoglycoprotein of human lymphocytes. II. Biochemical features.

B Axelsson, S Hammarström, J Finne, P Perlmann.   

Abstract

Large sialoglycoprotein of human lymphocytes (L-LSGP) from thymocytes and from peripheral blood lymphocytes (PBL) of normal donor and of B chronic lymphocytic leukemia (CLL) patients was purified by affinity chromatography to Maclura pomifera agglutinin (MPA)-Sepharose followed by preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). L-LSGP from the three different sources was very similar in amino acid composition. It contained a high proportion of acidic and hydroxy amino acids and also significant amounts of cysteine. No reduction in mobility in SDS-PAGE was noted for unreduced L-LSGP. The molecule may already in its native form have an extended conformation containing either free sulfhydryl groups or small S-S loops not affecting mobility in SDS-PAGE. L-LSGP was found to be highly glycosylated, the thymocyte glycoprotein containing somewhat less carbohydrate by weight (44%) than that of PBL (normal PBL 53% and B CLL 52%). This was due primarily to a lower content of sialic acid. The molecules contained mannose, galactose, N-acetyl galactosamine, N-acetylglucosamine and sialic acid in molar ratios 1.0:3.0:1.1:1.2:1.3 (thymocyte L-LSGP), 1.0:3.8:1.2:1.0:1.7 (PBL L-LSGP) and 1.0:3.5:2.2:1.3:2.8 (B CLL L-LSGP). The weak interaction of L-LSGP with lentil lectin, concanavalin A (Con A) and leucoagglutinin (La), its unchanged mobility in SDS-PAGE after tunicamycin treatment and its high amount of hydroxy amino acids suggest that most carbohydrate chains are O-glycosidically linked to the peptide chain. Native as well as Nase-treated L-LSGP show size microheterogeneity. This is probably due to small chemical differences in the L-LSGP molecules from different lymphocyte subsets.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3873337     DOI: 10.1002/eji.1830150503

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Parallel pattern of expression of CD43 and of LFA-1 on the CD45RA+ (naive) and CD45RO+ (memory) subsets of human CD4+ and CD8+ cells. Correlation with the aggregative response of the cells to CD43 monoclonal antibodies.

Authors:  R Youseffi-Etemad; B Axelsson
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

2.  Molecular heterogeneity of a lymphocyte glycoprotein in immunodeficient patients.

Authors:  D Reisinger; R Parkman
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

3.  CD43, the major sialoglycoprotein of human leukocytes, is proteolytically cleaved from the surface of stimulated lymphocytes and granulocytes.

Authors:  V Bazil; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

4.  Amino acid sequence of human plasma galactoglycoprotein: identity with the extracellular region of CD43 (sialophorin).

Authors:  K Schmid; M A Hediger; R Brossmer; J H Collins; H Haupt; T Marti; G D Offner; J Schaller; K Takagaki; M T Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

5.  Monoclonal antibodies to leucosialin (CD43) induce homotypic aggregation of the human mast cell line HMC-1: characterization of leucosialin on HMC-1 cells.

Authors:  S Weber; B Ruh; E Dippel; B M Czarnetzki
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

6.  Characterization of cDNAs encoding human leukosialin and localization of the leukosialin gene to chromosome 16.

Authors:  A Pallant; A Eskenazi; M G Mattei; R E Fournier; S R Carlsson; M Fukuda; J G Frelinger
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

7.  The sequence of rat leukosialin (W3/13 antigen) reveals a molecule with O-linked glycosylation of one third of its extracellular amino acids.

Authors:  N Killeen; A N Barclay; A C Willis; A F Williams
Journal:  EMBO J       Date:  1987-12-20       Impact factor: 11.598

8.  Monoclonal antibodies specific for interleukin 3-sensitive murine cells.

Authors:  R Palacios; T Neri; M Brockhaus
Journal:  J Exp Med       Date:  1986-02-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.